.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,265,392

« Back to Dashboard

Claims for Patent: 6,265,392

Title: Low oxygen content compositions of 1.alpha., 25-dihydroxycholeclciferol
Abstract:The invention relates to stable aqueous formulations comprising 1.alpha.,25-dihydroxycholecalciferol, a unit dose system comprising the same in a sealed vessel, and a process for preparing them.
Inventor(s): Abrahamson; Kent (Libertyville, IL), Anderson; Amy N. (Waukegan, IL), Grady; Haiyan (Mundelein, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:09/494,674
Patent Claims: 1. A stable composition comprising a therapeutically effective amount of 1.alpha.,25-dihydroxycholecalciferol in an aqueous solution having less than or equal to 2.0% oxygen in the headspace of a container when determined immediately after container sealing, said solution consisting essentially of a solubilizing agent and an antioxidant, wherein the solution has less than or equal to about one part per million (1 ppm) of aluminum during the shelf life of the composition.

2. The stable composition according to claim 1, wherein each milliliter (mL) of the solution consists essentially of:

a. about 1.0 to about 2.0 microgram (mcg) of 1.alpha.,25-dihydroxycholecalciferol;

b. at least 0.32% wt./wt. of solubilizing agent;

c. 0.001% to about 1.5% wt./wt. of antioxidant;

d. hydrochloric acid quantum sufficiat (q.s.);

e. sodium hydroxide q.s.; and

f. water for injection q.s.,

said solution in a sealed container having no more than about 2.0% of oxygen in the headspace of the container and having less than or equal to about 1 ppm of aluminum during the shelf life of the composition.

3. The stable composition according to claim 1, having 1.0 mcg of 1.alpha.,25-dihydroxycholecalciferol per 1 mL of solution.

4. The stable composition according to claim 1, having 2.0 mcg of 1.alpha.,25-dihydroxycholecalciferol per 1 mL of solution.

5. The stable composition according to claim 1, wherein the pH of the solution is between about 5.9 and about 8.5.

6. The stable composition according to claim 1, wherein the pH of the solution is about 7.0.

7. The stable composition according to claim 1, wherein the solubilizing agent is a polyoxyalkylene compound, alcohol, or polysorbate compound.

8. The stable composition according to claim 1, wherein the solubilizing agent is dimethylacetamide, polyethylene glycol 400 (PEG 400), polyethylene glyclol 200 (PEG 200), ethanol, isopropanol, 1,3-butanediol, propylene glycol, dimethylsulfoxide, glycerin, polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80.

9. The stable composition according to claim 1, wherein the solubilizing agent is ascorbic acid, a metal ascorbate, sodium bisulfite, sodium metabisulfite, ascorbyl palmitate, sodium sulfite, sodium formaldehyde sulfoxylate, acetone sodium bisulfite, tocopherol, dilaurylthiodipropionate, thioglycerol, monothioglycerol, norhydroguaianetic acid, an ascorbic acid ester, thioglycolic acid, or thiorthodipropionic acid.

10. The stable composition according to claim 1, wherein the solubilizing agent is ascorbic acid, a metal ascorbate, or an ascorbic acid ester.

11. The stable composition according to claim 1, wherein the solubilizing agent is sodium ascorbate.

12. The stable composition according to claim 1, wherein the aqueous solution measures a mean color value of less than about 100 APHA units immediately after container sealing.

13. The stable composition according to claim 1, wherein the aqueous solution measures a mean color value of less than about 400 APHA units during the shelf life of the product.

14. The stable composition according to claim 1, wherein said container is a vial.

15. A unit dose system comprising an aqueous solution of a therapeutically effective amount of 1.alpha.,25-dihydroxycholecalciferol in a sealed vessel, said unit dose system having less than or equal to 2.0% oxygen in the headspace of the sealed vessel when determined immediately after sealing, said solution consisting essentially of a solubilizing agent and an antioxidant, wherein said solution has less than 1 ppm of aluminum during the shelf life of the unit dose system.

16. The unit dose system according to claim 15, comprising an aqueous solution of 1.alpha.,25-dihydroxycholecalciferol in a sealed vessel, wherein each mL of the aqueous solution consists essentially of:

a. about 1.0 mcg to about 2.0 mcg of 1.alpha.,25-dihydroxycholecalciferol,

b. at least 0.32% wt./wt. of solubilizing agent;

c. 0.001% to about 1.5% wt./wt. of antioxidant;

d. hydrochloric acid q.s.;

e. sodium hydroxide q.s.; and

f. water for injection q.s.;

wherein said solution has less than 1 ppm of aluminum during the shelf life of the unit dose system, said unit dose system having less than or equal to 2.0% of oxygen in the headspace of the sealed vessel.

17. The unit dose system according to claim 16, wherein the sealed vessel is a unit dose vial.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc